Is It Time To Reassess Genmab (CPSE:GMAB) After Mixed Multi‑Year Share Performance

Get insights on thousands of stocks from the global community of over 7 million individual investors at Simply Wall St.

Wondering whether Genmab stock still offers value at current levels, or if the best of the opportunity is already behind it, starts with understanding what the recent price moves really say about expectations. Over the last week the stock is up 4.1%, while the 1 year return sits at 36.3%. This is even though the year to date return is a 12.4% decline and the 3 and 5 year returns are 38.7% and 21.2% declines respectively. These mixed returns have kept attention on Genmab, with recent coverage focusing on how the company fits into investors' portfolios as a large biotech stock and how sentiment has shifted around its long term potential. Articles have also highlighted how current pricing sits against analysts' expectations and different valuation frameworks, which helps explain some of the recent share price moves. Genmab currently has a valuation score of 4/6, reflecting the number of checks where the stock screens as undervalued. The rest of this article will compare the main valuation methods investors often use before turning to a more complete way of thinking about the stock's value.

Genmab delivered 36.3% returns over the last year. See how this stacks up to the rest of the Biotechs industry.

Approach 1: Genmab Discounted Cash Flow (DCF) Analysis

A Discounted Cash Flow, or DCF, model estimates what a company could be worth by projecting its future cash flows and discounting them back to today, so you can compare that value with the current share price.

For Genmab, the model uses a 2 Stage Free Cash Flow to Equity approach based on cash flow projections. The latest twelve-month free cash flow stands at about US$1.12b. Analyst projections extend to 2030, with free cash flow for that year estimated at US$2.33b, and further years extrapolated by Simply Wall St at modest steps beyond that level.

Putting these projections together, the DCF model points to an estimated intrinsic value of DKK 5,600.99 per share. Relative to the current share price, this implies the stock trades at a 68.6% discount, so on this model Genmab screens as materially undervalued.

Result: UNDERVALUED

Our Discounted Cash Flow (DCF) analysis suggests Genmab is undervalued by 68.6%. Track this in your watchlist or portfolio, or discover 228 more high quality undervalued stocks.GMAB Discounted Cash Flow as at May 2026

Head to the Valuation section of our Company Report for more details on how we arrive at this Fair Value for Genmab.

Approach 2: Genmab Price vs Earnings (P/E)

For profitable companies, the P/E ratio is a straightforward way to see how much investors are paying for each unit of current earnings, which helps you compare stocks that already generate profits.

Story Continues

What counts as a “normal” P/E depends on how quickly earnings are expected to change and how risky those earnings are. Higher expected growth and lower perceived risk usually support a higher P/E, while slower growth or higher uncertainty usually point to a lower P/E being more appropriate.

Genmab currently trades on a P/E of 17.6x. That sits below the Biotechs industry average of 27.7x and just under the peer average of 18.1x. Simply Wall St’s Fair Ratio for Genmab is 20.6x. This proprietary metric aims to estimate the P/E that might make sense for the stock given factors such as its earnings profile, industry, profit margins, market cap and stock specific risks.

Because the Fair Ratio blends these company specific inputs instead of relying only on broad industry or peer comparisons, it can give a more tailored view of value. With Genmab at 17.6x versus a Fair Ratio of 20.6x, the stock screens as undervalued on this approach.

Result: UNDERVALUEDCPSE:GMAB P/E Ratio as at May 2026

P/E ratios tell one story, but what if the real opportunity lies elsewhere? Start investing in legacies, not executives. Discover our 100 top founder-led companies.

Upgrade Your Decision Making: Choose your Genmab Narrative

Earlier it was mentioned that there is an even better way to understand valuation. Narratives on Simply Wall St give you a simple way to put a story behind the numbers by linking your view on Genmab, such as how its oncology pipeline, pricing pressure or cash position might play out, to a set of revenue, earnings and margin assumptions that flow through to a Fair Value you can compare with the current share price. These Narratives live in the Community page, update automatically as new news or earnings arrive, and can differ widely. For example, one bearish Genmab Narrative currently anchors on a Fair Value of about DKK 1,588 while a bullish Narrative sits near DKK 3,017. This helps you see exactly how different expectations about risks, growth and future P/E ratios translate into very different conclusions about whether the stock looks cheap or expensive today.

For Genmab however we will make it really easy for you with previews of two leading Genmab Narratives:

🐂 Genmab Bull Case

Fair value in this bullish Narrative: DKK 2,233.38

Implied discount to this fair value: about 21.3% versus the last close of DKK 1,758.50

Revenue growth assumption: 19.49% a year

Analysts behind this view see Genmab's broader antibody portfolio and late stage oncology assets as supporting higher long term earnings and a larger addressable market. The Narrative leans on recurring royalties from partnered drugs, growing contributions from wholly owned products and ongoing investment in commercial infrastructure. Key risks flagged include pricing pressure, regulatory uncertainty, dependence on major partners and the chance that some pipeline programs or acquisitions underdeliver.

🐻 Genmab Bear Case

Fair value in this bearish Narrative: DKK 1,588.21

Implied discount to this fair value: about 11.0% versus the last close of DKK 1,758.50

Revenue growth assumption: 17.01% a year

This view stresses Genmab's reliance on a small cluster of oncology products and the risk that pricing pressure, patent cliffs and competition limit future earnings. Higher R&D spend, regulatory complexity and potential delays to launches are central to the concern that profit margins could be squeezed over time. Even in this case, analysts still factor in ongoing revenue growth, but argue that execution and concentration risks justify a lower fair value and closer scrutiny of 2026 pipeline catalysts.

If you want to see how these narratives expand into full cash flow, earnings and risk assumptions for Genmab, the Community section on Simply Wall St lets you review them side by side and stress test which set of expectations lines up best with your own view of the stock.

To see how these results tie into long-term growth, risks, and valuation, check out the full range of community narratives for Genmab on Simply Wall St. Add the company to your watchlist or portfolio so you'll be alerted when the story evolves.

Do you think there's more to the story for Genmab? Head over to our Community to see what others are saying!CPSE:GMAB 1-Year Stock Price Chart

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Companies discussed in this article include GMAB.CO.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email [email protected]

View Comments